CY1111335T1 - Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης - Google Patents

Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης

Info

Publication number
CY1111335T1
CY1111335T1 CY20111100279T CY111100279T CY1111335T1 CY 1111335 T1 CY1111335 T1 CY 1111335T1 CY 20111100279 T CY20111100279 T CY 20111100279T CY 111100279 T CY111100279 T CY 111100279T CY 1111335 T1 CY1111335 T1 CY 1111335T1
Authority
CY
Cyprus
Prior art keywords
diseases
alkyl
phosphols
preparations
under
Prior art date
Application number
CY20111100279T
Other languages
English (en)
Inventor
Hansjörg Eibl
Susanne Christine Wieland-Berghausen
Jean Steffan
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004050910A external-priority patent/DE102004050910A1/de
Priority claimed from DE102004055284A external-priority patent/DE102004055284A1/de
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of CY1111335T1 publication Critical patent/CY1111335T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

Η παρούσα αφορά νέα παρασκευάσματα φαρμάκων, τα οποία σαν δραστικές ουσίες περιέχουν αλκυλοφωσφοχολίνες και ανάλογα, αλκυλ-αλκανοδιολο-φωσφοχολίνες και ανάλογα καθώς και (αιθερο)-λυσολεκιθίνες και ανάλογα σε διαφορετικές μορφές διεξαγωγής, δραστικές ουσίες είναι εδώ ενσωματωμένα συστατικά λιποσωμάτων, τα οποία περιέχουν ακόμη χοληστερίνη και ανάλογα καθώς και έναν αρνητικό φορέα φόρτισης. Τα παρασκευάσματα φαρμάκων είναι ιδιαίτερα κατάλληλα για τη θεραπεία και/ή την προφύλαξη καρκίνου, ασθενειών πρωτόζωων, όπως λεϊσμανιώσεις και ασθένειες αμοιβάδων, ακαρίωσης και ασθενειών, οι οποίες προκαλούνται από αρθρόποδα καθώς και βακτηριακών ασθενειών, όπως π.χ. ερλιχίωση. Επίσης μπορούν να επηρεάζονται ευνοϊκά ασθένειες οφθαλμών, οι οποίες συνοδεύονται με ανεξέλεγκτες κυτταρικές διαδικασίες.
CY20111100279T 2004-10-19 2011-03-11 Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης CY1111335T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004050910A DE102004050910A1 (de) 2004-10-19 2004-10-19 Formulierungen mit Alkylphosphocholinen unter Verwendung von neuen negativen Ladungsträgern
DE102004055284A DE102004055284A1 (de) 2004-11-16 2004-11-16 Formulierungen mit Alkylphosphocholinen unter Verwendung von neuen negativen Ladungsträgern
EP05795350A EP1827379B8 (de) 2004-10-19 2005-10-19 Formulierungen mit alkylphosphocholinen unter verwendung von neuen negativen ladungsträgern

Publications (1)

Publication Number Publication Date
CY1111335T1 true CY1111335T1 (el) 2015-08-05

Family

ID=36203318

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100279T CY1111335T1 (el) 2004-10-19 2011-03-11 Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης

Country Status (12)

Country Link
US (1) US8828972B2 (el)
EP (1) EP1827379B8 (el)
JP (1) JP2008517023A (el)
KR (1) KR101311980B1 (el)
AT (1) ATE491437T1 (el)
BR (1) BRPI0516937A (el)
CA (1) CA2584537C (el)
CY (1) CY1111335T1 (el)
DE (1) DE502005010699D1 (el)
DK (1) DK1827379T3 (el)
PT (1) PT1827379E (el)
WO (1) WO2006042751A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
KR101492290B1 (ko) * 2007-07-20 2015-02-11 코세 코퍼레이션 베시클 조성물, 및 피부 외용제
DE102009007853A1 (de) * 2009-02-06 2010-08-12 LMU Ludwig-Maximilians-Universität München Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe
ES2350075B1 (es) * 2009-05-11 2011-11-10 Maria Pilar Mateo Herrero Composicion microencapsulada a base de olea europaea saponificada, suuso y su procedimiento de obtencion.
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
CN105326824A (zh) * 2015-11-06 2016-02-17 暨南大学 棕榈酸在制备杀灭水产动物体外寄生虫药物中的应用
KR102330620B1 (ko) 2020-05-18 2021-11-23 한림대학교 산학협력단 옴진드기 감염의 진단 및 치료 모니터링을 위한 정보 제공 방법
KR20230131324A (ko) 2022-03-03 2023-09-13 한림대학교 산학협력단 핵산 기반의 측면 흐름 분석을 이용한 옴진드기 진단용 정보 제공 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
DE3474511D1 (en) * 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0357773B1 (en) * 1987-02-27 1992-07-15 Terumo Kabushiki Kaisha Process for preparing liposomes
JPH01180245A (ja) 1988-01-12 1989-07-18 Terumo Corp リポソーム
DE4132345A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
DE4308121A1 (de) * 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
PT785773E (pt) * 1994-10-14 2001-05-31 Liposome Co Inc Lipossomas de eteres lipidicos e sua utilizacao terapeutica
US5711964A (en) * 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5932242A (en) * 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
EP1135193B1 (de) 1998-12-04 2002-10-30 Max-Delbrück-Centrum Für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
JP4444385B2 (ja) 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
GB9918670D0 (en) * 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10148067A1 (de) 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
DE10242367A1 (de) * 2002-09-12 2004-03-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Thermolabiles Liposom mit geregelter Freigabetemperatur

Also Published As

Publication number Publication date
KR20070074626A (ko) 2007-07-12
US8828972B2 (en) 2014-09-09
WO2006042751A3 (de) 2007-07-19
JP2008517023A (ja) 2008-05-22
EP1827379B1 (de) 2010-12-15
US20080090781A1 (en) 2008-04-17
ATE491437T1 (de) 2011-01-15
CA2584537A1 (en) 2006-04-27
KR101311980B1 (ko) 2013-09-26
PT1827379E (pt) 2011-03-23
WO2006042751A2 (de) 2006-04-27
EP1827379A2 (de) 2007-09-05
CA2584537C (en) 2013-09-24
DK1827379T3 (da) 2011-04-04
EP1827379B8 (de) 2011-05-25
DE502005010699D1 (de) 2011-01-27
BRPI0516937A (pt) 2008-09-23

Similar Documents

Publication Publication Date Title
CY1111335T1 (el) Παρασκευασματα με αλκυλοφωσφοχολινες κατω απο χρησιμοποιηση νεων αρνητικων φορεων φορτισης
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BRPI0512108A (pt) antibióticos contendo complexos de ácido borìnico e métodos de uso
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200970110A1 (ru) Производные 6,9-дизамещённого пурина и их применение для лечения кожи
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
TW200503674A (en) Therapeutic agents
CA2690111A1 (en) Anthelmintic combination
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
HK1102702A1 (en) Anti-viral uses of borinic acid complexes
EA200602092A1 (ru) Способ и композиция для лечения ринита
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
SG155939A1 (en) Phosphoindoles as hiv inhibitors
HUP0400368A2 (hu) Oxitocin agonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk szexuális zavarok kezelésére
UY28366A1 (es) Compuestos químicos
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
TW200609222A (en) Diazole derivatives
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
TW200610530A (en) Anti-parasitic uses of borinic acid complexes
BRPI0719826A8 (pt) Composição sólida termoestável, e, processo de preparar uma composição farmacêutica sólida
EA200870195A1 (ru) Новые композиции пестицидов
PT1904511E (pt) Homogemcitabinas
MY169533A (en) Use of azithromycin for the manufacture of a medicament for treating ocular infections